Bio-Techne Corp (TECH) has been given a "Moderate Buy" consensus recommendation by brokerages, despite multiple headwinds in Q1. Meanwhile, Mitsubishi UFJ Trust & Banking Corp has lowered its position in the company. Shares of the company are estimated to be 32% above their intrinsic value. Several investment firms including Bessemer Group Inc. and Vanguard Group Inc. have boosted their positions in TECH stock. In recent developments, Bio-Techne has announced a new distribution agreement with Thermo Fisher Scientific and has highlighted the use of its proprietary technology in top-line biomarker data from Regulus Therapeutics.
There has also been significant activity from investment groups, with Janney Montgomery Scott LLC, Allspring Global Investments Holdings LLC and many others boosting their positions, with others like Clearbridge Investments LLC and US Bancorp DE reducing their shares. The company's notable achievements include surpassing 10,000 peer-reviewed publications citing RNAscope Technology and receiving European IVDR certification for a chronic myeloid leukemia diagnostic. Furthermore, their collaboration with Nikon Instruments and successful acquisitions of Lunaphore and NamoCell underline their commitment to expanding access to innovative spatial biology services.
Bio-Techne Corp TECH News Analytics from Thu, 07 Jun 2018 07:00:00 GMT to Sun, 28 Jul 2024 08:21:38 GMT - Rating 6 - Innovation 7 - Information 8 - Rumor 3
